test

Available Trials

Latest Clinical Trials

10
(Novartis Signature) Modular phase II study to link targeted therapy to patients with pathway activated tumors: Module 4 - LGX818 for patients with BRAFV600 mutated tumors
Disease/Condition: Bladder | Brain and Nervous System | Breast - Female | Esophagus | Eye and Orbit | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Liver | Lung | Melanoma, skin | Other Skin | Ovary | Pancreas | Prostate | Rectum | Small Intestine | Soft Tissue | Stomach
Principal Investigator: Joseph Paul Eder
19F-MRS (Magnetic Resonance Spectroscopy) Studies of in-vivo 5-Fluorouracil Pharmacokinetics with and without Bevacizumab in Patients with Liver Metastases from Adenocarcinoma of the Colon
Disease/Condition: Colon | Colon Cancer
Principal Investigator: Howard Hochster
A Multi-arm Phase I Safety Study of Nivolumab in Combination with Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects with Stage IIIB/IV Non-small Cell Lung Cancer
Disease/Condition: Lung
Principal Investigator: Scott Gettinger
A Multi-institutional Feasibility Study of Intra-Arterial Chemotherapy Given in the Ophthalmic Artery of Children with Retinoblastoma: A Limited Institution Pilot Study
Principal Investigator: Nina Kadan-Lottick
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of SGN-LIV1A in Patients with LIV-1-Positive Metastatic Breast Cancer
Disease/Condition: Breast - Female
Principal Investigator: Lajos Pusztai
A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination with Tremelimumab in Subjects With Advanced Non-Small Cell Lung Cancer
Disease/Condition: Lung
Principal Investigator: Sarah Goldberg
A Phase 1b Study of the Safety and Pharmacology of MPDL3280A Administered with Ipilimumab or Interferon-alpha in Patients with Locally Advanced or Metastatic Solid Tumors
Principal Investigator: Mario Sznol
A Phase 1b/2 Study of OMP-59R5 in Combination with Etoposide and Cisplatin in Subjects with Untreated Extensive Stage Small Cell Lung Cancer (PINNACLE)
Disease/Condition: Lung
Principal Investigator: Anne Chiang
A Phase I Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Patients With Locally Advanced or Metastatic Solid Tumors And in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Disease/Condition: Anus | Bladder | Breast - Female | Breast - Male | Cervix Uteri | Colon | Esophagus | Kidney | Larynx | Liver | Lung | Other Digestive Organ | Other Endocrine System | Other Female Genital | Other Male Genital | Other Respiratory and Intrathoracic Organs
Principal Investigator: Lajos Pusztai
A Phase I Dose Finding Study of Belinostat plus Cyclophosphamide/Vincristine/Doxorubicin/Prednisone (CHOP) Regimen (BelCHOP) for Treatment of Patients with Peripheral T Cell Lymphoma (PTCL)
Disease/Condition: Non-Hodgkin's Lymphoma
Principal Investigator: Francine Foss
A Phase I Open label, Dose Finding Study of IMCgp100 in Patients with Advanced Malignant Melanoma
Disease/Condition: Melanoma, skin
Principal Investigator: Mario Sznol
A Phase I Study of the Safety and Pharmacokinetics of Escalating Doses of AGS15E Given as Monotherapy in Subjects with Metastatic Urothelial Cancer
Disease/Condition: Bladder
Principal Investigator: Daniel Petrylak
A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumors
Disease/Condition: Breast - Female | Colon | Esophagus | Kidney | Liver | Lung | Melanoma, skin | Pancreas
Principal Investigator: Joseph Paul Eder
A Phase I, Open-label, dose-escalation study of the safety and pharmacokinetics of MPDL3280A administered intravenously as a single agent to patients with locally advanced or metastatic solid tumors or hematologic malignancies
Disease/Condition: Bladder | Brain and Nervous System | Breast - Female | Colon | Esophagus | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Liver | Lung | Melanoma, skin | Multiple Myeloma | Non-Hodgkin's Lymphoma | Other Male Genital | Pancreas | Prostate | Rectum | Soft Tissue | Stomach | Thyroid
Principal Investigator: Roy Herbst
A Phase I, Open-Label, Multiple Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Subjects with Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Disease/Condition: Breast - Female | Colon | Lung | Melanoma, skin | Ovary | Rectum | Stomach
Principal Investigator: Joseph Paul Eder
A Phase I/II Study of HSP90 Inhibitor AT13387 Alone and in Combination with Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC)
Disease/Condition: Lung
Principal Investigator: Scott Gettinger
A Phase I/II Study of the Combination of BKM120 and Bevacizumab, Glioblastoma Multiforme
Disease/Condition: Brain and Nervous System
Principal Investigator: Kevin Becker
A Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T cells against Cancer-testis Antigens in Metastatic Melanoma
Disease/Condition: Melanoma, skin
Principal Investigator: Harriet Kluger
A Phase I/II, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors
Disease/Condition: Bladder | Breast - Female | Lung | Pancreas | Stomach
Principal Investigator: Joseph Paul Eder
A Phase I/IIa, First Time in human, open-label dose-escalation study of GSK2636771 in subjects with advanced solid tumors with PTEN deficiency
Disease/Condition: Brain and Nervous System | Breast - Female | Breast - Male | Breast Cancer (ER, PR, and HER2 negative) | Colon | Colorectal Cancer | Endometrial Cancer | Gastric Adenocarcinoma | Glioblastoma Multiforme | Head/ Neck Squamous Cell Carcinoma | Lip, Oral Cavity and Pharynx | Lung | Melanoma | Melanoma, skin | Non-Small Cell Lung Cancer (NSCLC) | Other Female Genital | Ovarian Cancer | Ovary | Prostate | Prostate Cancer | Rectum | Stomach
Principal Investigator: Joseph Paul Eder
A Phase Ib Multi-Cohort Study of MK-3475 in Subjects with Advanced Solid Tumors
Disease/Condition: Bladder | Breast - Female | Lip, Oral Cavity and Pharynx | Stomach
Principal Investigator: Lajos Pusztai
A Phase Ib Study of the Safety and Pharmacology of MPDL3280A Administered with Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer
Disease/Condition: Lung
Principal Investigator: Scott Gettinger
A Phase II Multi-center, Randomized, Placebo-Controlled Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients with Metastatic Colorectal Cancer
Disease/Condition: Colon
Principal Investigator: Howard Hochster
A Phase II Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients with Refractory Gastrointestinal Stromal Tumor
Disease/Condition: Cancer | Other Digestive Organ
Principal Investigator: Howard Hochster
A Phase II Study of MK-3475 in Patients with Metastatic Melanoma or Non-Small Cell Lung Cancer with Untreated Brain Metastases
Disease/Condition: Lung | Melanoma, skin
Principal Investigator: Harriet Kluger
A Phase II Study of Stereotactic Radiosurgery or Other Local Ablation Followed by Erlotinib for Patients with EGFR Mutation Who Have Previously Progressed on an EGFR Tyrosine Kinase Inhibitor (TKI)
Disease/Condition: Lung
Principal Investigator: Roy Decker
A Phase II Trial of Carboplatin/Paclitaxel with and without Trastuzumab in HER2/neu+ Patients with Advanced orRecurrent Uterine Serous Papillary Cancer
Disease/Condition: Corpus Uteri
Principal Investigator: Alessandro Santin
A Phase II Trial of Response-Based Radiation Therapy for Pediatric Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT)
Disease/Condition: Brain and Nervous System
Principal Investigator: Nina Kadan-Lottick
A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients with Sickle Cell-Related Pain Crises
Disease/Condition: Ill-Defined Sites | Unknown Sites
Principal Investigator: John Roberts
A Phase II, Multicenter, Single-Arm Study of MPDL3280A in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Disease/Condition: Bladder
Principal Investigator: Daniel Petrylak
A Phase II, Multicenter, Single-Arm Study OF MPDL3280A in Patients with PD-L1−Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Disease/Condition: Lung
Principal Investigator: Scott Gettinger
A Phase II, Randomized Study of MPDL3280A Administered as Monotherapy or in Combination with Avastin (Bevacizumab) versus Sunitinib in Patients with Untreated Advanced Renal Cell Carcinoma
Disease/Condition: Kidney
Principal Investigator: Mario Sznol
A Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer
Disease/Condition: Lung
Principal Investigator: Roy Herbst
A Phase II/III Randomized Trial of Two Doses of MK-3475 (SCH900475) versus Docetaxel in Previously Treated Subjects with Non-Small Cell Lung Cancer
Disease/Condition: Lung
Principal Investigator: Roy Herbst
A Phase IIb, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects with Unresectable Pleural or Peritoneal Malignant Mesothelioma
Disease/Condition: Lung
Principal Investigator: Sarah Goldberg
A Phase III Randomized Double-Blind Trial of Maintenance with Niraparib Versus Placebo in Patients with Platinum Sensitive Ovarian Cancer
Principal Investigator: Masoud Azodi
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
Disease/Condition: Prostate
Principal Investigator: Daniel Petrylak
A Phase III Randomized Trial for Patients with de novo AML using Bortezomib and Sorafenib for patients with High Allelic Ratio FLT3/ITD
Disease/Condition: Cancer | Myeloid and Monocytic Leukemia
Principal Investigator: Nina Kadan-Lottick
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-negative B lineage Acute Lymphoblastic Leukemia in Adults
Disease/Condition: Leukemia, other
Principal Investigator: Steven Gore
A Phase III Randomized Trial of Chemotherapy with or without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer (ECOG E1305)
Disease/Condition: Head and Neck Cancer | Larynx | Lip, Oral Cavity and Pharynx
Principal Investigator: Hari Deshpande
A Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer
Disease/Condition: Breast - Female | Breast - Male | Cancer
Principal Investigator: Maysa Abu-Khalaf
A Phase III Study of Chlorhexidine Gluconate Cleansing in Preventing Central Line Associated Bloodstream Infection and Acquisition of Multi-drug Resistant Organisms in Younger Patients With Cancer or Undergoing Donor Stem Cell Transplant
Principal Investigator: Nina Kadan-Lottick
A Phase III Study of Risk Directed Therapy for Infants with Acute Lymnphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +-FLT3 Inhibition
Disease/Condition: Leukemia, other
Principal Investigator: Nina Kadan-Lottick
A Phase III Trial of Adjuvant Chemotherapy as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The Outback Trial
Principal Investigator: Peter Schwartz
A Phase III, Double Blind, Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)
Disease/Condition: Colon
Principal Investigator: Sajid Khan
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER-2 Negative Breast Cancer with Recurrence Score (RS) of 25 or Less (SWOG S1007) (CIRB)
Disease/Condition: Breast - Female
Principal Investigator: Erin Hofstatter
A phase III, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects with Metastatic Renal Cell Carcinoma that has progressed after prior VEGFR Tyrosine Kinase Inhibitor Therapy
Principal Investigator: Harriet Kluger
A Phase III, Randomized, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients with BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer following First Line Platinum Based Chemotherapy.
Principal Investigator: Thomas Rutherford
A Pilot Pre-operative Window Trial of Black Cohosh in Women with Ductal Carcinoma in situ
Disease/Condition: Breast - Female
Principal Investigator: Erin Hofstatter
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Disease/Condition: Anus | Colon
Principal Investigator: Neal Fischbach
A Randomized Phase II Study of Exercise and Metformin in Colorectal and Breast Cancer Survivors
Principal Investigator: Melinda Irwin
A Randomized Phase II trial of Neoadjuvant Cisplatin vs. Doxorubicin/Cyclophosphamide (AC) in Women with Newly Diagnosed Breast Cancer and Germline BRCA Mutations
Disease/Condition: Breast - Female | Breast - Male
Principal Investigator: Erin Hofstatter
A Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer
Disease/Condition: Pancreas
Principal Investigator: Stacey Stein
A Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered With Concurrent Cisplatin Versus Docetaxel Versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck (RTOG 1216)
Principal Investigator: Roy Decker
A Randomized Phase III open Label Study of Nivolumab versus Bevacizumab and a Safety Study of Nivolumab or Nivolumab in Combination with Ipilimumab in Adult Subjects with Recurrent Glioblastoma (GBM)
Disease/Condition: Brain and Nervous System
Principal Investigator: Joachim Baehring
A Randomized Phase III Study Comparing Cabazitaxel/Prednisone in Combination with Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men with Metastatic Castrate Resistant Prostate Cancer
Disease/Condition: Prostate
Principal Investigator: Daniel Petrylak
A Randomized Phase III Study of Standard Cytarabine Plus Daunomycin (7+3) Therapy versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)
Disease/Condition: Myeloid and Monocytic Leukemia
Principal Investigator: Nikolai Podoltsev
A Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid) Alone and in Combination with Epoetin Alfa (Procrit) in Subjects with Low- or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) and Symptomatic Anemia
Disease/Condition: Myeloid and Monocytic Leukemia
Principal Investigator: Steven Gore
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Disease/Condition: Breast - Female | Breast Cancer
Principal Investigator: Erin Hofstatter
A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of Brentuximab Vedotin and CHP (A+CHP) versus CHOP in the Frontline Treatment of Patients with CD30- Positive Mature T-cell Lymphomas
Disease/Condition: Non-Hodgkin's Lymphoma
Principal Investigator: Francine Foss
A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Evaluate the Efficacy and Safety of Afatinib (BIBW 2992) as Adjuvant Therapy After Chemo-Radiotherapy in Primary Unresected Patients with Stage III, IVa, or IVb Loco-Regionally Advanced Head and Neck Squamous Cell Carcinoma
Disease/Condition: Brain and Nervous System | Other Respiratory and Intrathoracic Organs
Principal Investigator: Anne Chiang
A RANDOMIZED, MULTICENTER, ADAPTIVE PHASE II/III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TRASTUZUMAB EMTANSINE (T-DM1) VERSUS TAXANE (DOCETAXEL OR PACLITAXEL) IN PATIENTS WITH PREVIOUSLY TREATED LOCALLY ADVANCED OR METASTATIC HER2-POSITIVE GASTRIC CANCER, INCLUDING ADENOCARCINOMA OF THE GASTROESOPHAGEAL JUNCTION
Disease/Condition: Adenocarcinoma of the Gastroesophageal Junction | Esophagus | Gastric Cancer | Stomach
Principal Investigator: Howard Hochster
A Randomized, Multicenter, Open-label Phase III Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine versus Trastuzumab as Adjuvant Therapy for Patients with HER2-Positive Primary Breast Cancer who have Residual Tumor Present Pathologically in the Breast or Axillary Lymph Nodes following Preoperative Therapy (NSABP B50/Katherine Study)
Disease/Condition: Breast - Female | Breast - Male
Principal Investigator: Michael DiGiovanna
A Randomized, Open-Label, Phase II Study of Sipuleucel-T with Concurrent vs Sequential Administration of Enzalutamide in Men with Metastatic Castrate Resistant Prostate Cancer
Disease/Condition: Prostate
Principal Investigator: Daniel Petrylak
A Randomized, Phase 2, Open-Label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects with High Risk HER2+ Urothelial Carcinoma
Disease/Condition: Bladder | Cancer
Principal Investigator: Hari Deshpande
A Single Arm, Neoadjuvant, Phae II Trial of Pertuzumab and Trastuzumab Administered Concomitantly with Weekly Paclitaxel and FEC for Clinical Stage I-III HER2-Positive Breast Cancer
Disease/Condition: Breast - Female
Principal Investigator: Lajos Pusztai
A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Principal Investigator: Thomas Rutherford
ACRIN 6690: A Prospective, Multicenter Comparison of Multiphase Contrast-Enhanced CT and Multiphase Contrast-Enhanced MRI for Diagnosis of Hepatocellular Carcinoma and Liver Transplant Allocation
Disease/Condition: Liver | Liver Cancer
Principal Investigator: Jeffrey Weinreb
Active Surveillance of the Small Renal Mass: An Integrated Biomarker Trial
Principal Investigator: Brian Shuch
An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma
Disease/Condition: Brain and Nervous System | Glioblastoma
Principal Investigator: Kevin Becker
An Open Label, Phase I/IIa, Dose Escalation Trial to Investigate the Maximum Tolerated Dose, Safety, Pharmacokinetics, and Efficacy of Intravenous Volasertib (BI 6727) in Combination with Decitabine in Patients with Acute Myeloid Leukemia
Disease/Condition: Leukemia, not otherwise specified | Myeloid and Monocytic Leukemia
Principal Investigator: Nikolai Podoltsev
An Open-label, Randomized Phase III Study of Inotuzumab Ozogamicin Compared to a Defined Investigator's Choice in Adult Patients with Relapsed or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL)
Disease/Condition: Leukemia, other
Principal Investigator: Nikolai Podoltsev
Assessment of the Decision-making Impact of the Breast Cancer Index in Recommending Extended Adjuvant Endocrine Therapy for Patients with Early Stage ER-positive Breast Cancer
Principal Investigator: Tara Sanft
Characterization of Tumor Cells in the Arterial and Venous Circulations of Non Small Cell Lung Cancer Patients
Disease/Condition: Non Small Cell Lung Cancer
Principal Investigator: Daniel J. Boffa
Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma
Disease/Condition: Adult Rhabdomyosarcoma | Childhood Desmoplastic Small Round Cell Tumor | Chordoma | Desmoid Tumor | Metastatic Childhood Soft Tissue Sarcoma | Nonmetastatic Childhood Soft Tissue Sarcoma | Previously Treated Childhood Rhabdomyosarcoma | Previously Untreated Childhood Rhabdomyosarcoma | Recurrent Adult Soft Tissue Sarcoma | Recurrent Childhood Rhabdomyosarcoma | Recurrent Childhood Soft Tissue Sarcoma | Soft Tissue | Stage I Adult Soft Tissue Sarcoma | Stage II Adult Soft Tissue Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma
Principal Investigator: Nina Kadan-Lottick
Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma
Disease/Condition: Adult Supratentorial Primitive Neuroectodermal Tumor (PNET) | Childhood Supratentorial Primitive Neuroectodermal Tumor | Ewing Sarcoma of Bone | Extraosseous Ewing Sarcoma | Extraosseous Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Peripheral Primitive Neuroectodermal Tumor of the Kidney | Soft Tissue | Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
Principal Investigator: Gary Kupfer
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Liver Cancer
Disease/Condition: Childhood Hepatoblastoma | Liver | Stage I Childhood Liver Cancer | Stage II Childhood Liver Cancer | Stage III Childhood Liver Cancer | Stage IV Childhood Liver Cancer
Principal Investigator: Nina Kadan-Lottick
CPX-351 IN PATIENTS 60-75 YEARS OF AGE WITH AML
Disease/Condition: Leukemia, other
Principal Investigator: Nikolai Podoltsev
Defibrotide for Patients with Hepatic Veno-Occlusive Disease (VOD)
Disease/Condition: Hepatic Veno-Occlusive Disease | Hodgkin's Lymphoma | Leukemia, not otherwise specified | Multiple Myeloma | Non-Hodgkin's Lymphoma
Principal Investigator: Stuart Seropian
Examination of Epigenetic Changes in Breast Tissue and Peripheral Blood of Women at Average versus Increased Risk of Breast Cancer
Disease/Condition: Breast Cancer | Cancer
Principal Investigator: Erin Hofstatter
Expanded Access of MK-3475 in Metastatic Melanoma Patients with Limited to No Treatment Options
Principal Investigator: Mario Sznol
Expanded Access Program with Nivolumab (BMS-936558) in Combination with Ipilimumab (Yervoy) in Anti-CLTA-4 Treatment-Naïve Subjects with Unresectable or Metastatic Melanoma
Disease/Condition: Melanoma, skin
Principal Investigator: Mario Sznol
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
Disease/Condition: Bladder | Distal Urethral Cancer | Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter | Proximal Urethral Cancer | Recurrent Bladder Cancer | Recurrent Prostate Cancer | Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter | Recurrent Urethral Cancer | Stage IV Bladder Cancer | Stage IV Prostate Cancer | Transitional Cell Carcinoma of the Bladder | Urethral Cancer Associated With Invasive Bladder Cancer
Principal Investigator: Hari Deshpande
Health Effects After Anthracycline and Radiation Therapy (HEART): Dexrazoxane and Prevention of Anthracycline-related Cardiomyopathy
Principal Investigator: Nina Kadan-Lottick
Improving Adherence to Oral Cancer Agents and Self Care of Symptoms Using an IVR
Disease/Condition: Cancer
Principal Investigator: Elizabeth Ercolano
IncobotulinumtoxinA for Treatment of Focal Cancer Pain After Surgery and/or Radiation
Disease/Condition: Ill-Defined Sites | Pain
Principal Investigator: Bahman Jabbari
Intergroup Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Evaluation of Rituximab Efficacy and Safety in High Risk Patients - Phase III Trial
Disease/Condition: Leukemia, other
Principal Investigator: Nina Kadan-Lottick
Intra-Operative Specimen Imaging in Breast Cancer Patients Undergoing Standard Partial Mastectomy: A Pilot of the Faxitron BioVision Wedge 3D versus BioVision 2D Imaging
Disease/Condition: Breast Cancer | Cancer
Principal Investigator: Anees Chagpar
LAASR: Laser Ablation After Stereotactic Radiosurgery
Disease/Condition: Brain and Nervous System
Principal Investigator: Veronica Chiang
Longitudinal Assessment and Functional Outcomes in Patients with Hematologic Malignancies and Related Disorders
Disease/Condition: Hematologic Malignancies
Principal Investigator: Stephanie Halene
Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma
Disease/Condition: Brain and Nervous System | Childhood Infratentorial Ependymoma | Childhood Supratentorial Ependymoma | Newly Diagnosed Childhood Ependymoma
Principal Investigator: Nina Kadan-Lottick
Molecular Predictors of Radiation Resistance
Disease/Condition: Unknown Sites
Principal Investigator: Joseph Contessa
My Pathway: An Open Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib, and Vismodegib in Patients Who Have Advanced Cancer with Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents PRO-02
Disease/Condition: Bladder | Brain and Nervous System | Breast - Female | Colon | Esophagus | Lip, Oral Cavity and Pharynx | Liver | Lung | Melanoma, skin | Other Endocrine System | Ovary | Pancreas | Prostate | Rectum | Small Intestine | Soft Tissue | Stomach | Thyroid
Principal Investigator: Joseph Paul Eder
Neuroblastoma Antibody Study
Disease/Condition: Brain and Nervous System | Disseminated Neuroblastoma | Localized Resectable Neuroblastoma | Localized Unresectable Neuroblastoma | Regional Neuroblastoma | Stage 4S Neuroblastoma
Principal Investigator: Nina Kadan-Lottick
Newly Diagnosed High Risk B-Precursor ALL - Clofarabine
Disease/Condition: Leukemia, not otherwise specified
Principal Investigator: Nina Kadan-Lottick
Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 (mogamulizumab) Versus Vorinostat in Subjects with Previously Treated Cutaneous T-Cell Lymphoma
Disease/Condition: Non-Hodgkin's Lymphoma
Principal Investigator: Francine Foss
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery
Disease/Condition: Colon | Colorectal Cancer
Principal Investigator: Howard Hochster
PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma
Disease/Condition: Limited-stage Diffuse Large B-Cell Lymphoma | Non-Hodgkin's Lymphoma
Phase 1b/2, Multicenter, Open-label Study of Carfilzomib, Carboplatin, and Etoposide in Subjects with Previously Untreated Extensive-stage Small-cell Lung Cancer
Disease/Condition: Lung
Principal Investigator: Anne Chiang
Phase 2 Single Arm, Two Cohort Study Evaluating AMG 337 in Subjects with MET Amplif. GI/GEJ/E cancer
Disease/Condition: Esophagus | Stomach
Principal Investigator: Howard Hochster
Phase 2 Study of Cabazitaxel in Refractory Metastatic Gastric and Gastroesophageal Adenocarcinoma
Disease/Condition: Esophagus | Other Digestive Organ
Principal Investigator: Jeremy Kortmansky
Phase 2 study of PF-05212384 plus irinotecan vs. cetuximab plus irinotecan in KRAS & NRAS wt mCLC
Disease/Condition: Anus | Colon
Principal Investigator: Howard Hochster
Phase 3 Study of Adjuvant Regorafenib vs. Placebo for Patients with Stage 4 colorectal cancer
Disease/Condition: Colon | Liver | Rectum
Principal Investigator: Howard Hochster
Phase I Study of BVD-523 in Patients with Advanced Malignancies
Disease/Condition: Melanoma, skin
Phase Ib Trial of MPDL3280A with Bevacizumab or with Bevacizumab + FOLFOX in Patients with Solid Tumors
Disease/Condition: Colon | Lung | Rectum
Principal Investigator: Howard Hochster
Phase Ib/II study of LGX818 and cetuximab or LGX818, BYL719 and cetuximab in BRAF mutant mCRC
Disease/Condition: Colon | Rectum
Principal Investigator: Howard Hochster
Phase II neoadjuvant vemurafenib trial in melanoma patients with untreated brain metastases with B-raf mutations
Disease/Condition: Cancer | Melanoma, skin
Principal Investigator: Harriet Kluger
Phase II Study of Peri-Operative Modified Folfirinox in Localized Pancreatic Cancer
Disease/Condition: Pancreas
Principal Investigator: Jill Lacy
Phase II, Open Label Study of the Effect of GTx-758 as Secondary Hormonal Therapy on Serum PSA and Serum Free Testosterone Levels in Men with Metastatic Castration Resistant Prostate Cancer Maintained on Androgen Deprivation Therapy
Disease/Condition: Prostate
Principal Investigator: Daniel Petrylak
Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer (RTOG 0920) (CIRB)
Disease/Condition: Head and Neck Cancer | Larynx | Lip, Oral Cavity and Pharynx
Principal Investigator: Roy Decker
Pilot Trial of KD018 with Neo-Adj Concurrent Chemo-RT in PTs with Rectal CA
Disease/Condition: Rectum
Principal Investigator: Susan Higgins
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
Disease/Condition: Adenocarcinoma of the Esophagus | Adenocarcinoma of the Gastroesophageal Junction | Esophagus | Stage IB Esophageal Cancer | Stage IIA Esophageal Cancer | Stage IIB Esophageal Cancer | Stage IIIA Esophageal Cancer | Stage IIIB Esophageal Cancer
Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer
Disease/Condition: Esophagus
Principal Investigator: Daniel Boffa
Risk-Adapted Chemotherapy in Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia
Disease/Condition: B-cell Childhood Acute Lymphoblastic Leukemia | Leukemia | Lymphoid Leukemia | Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia | Untreated Adult Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic Leukemia
Principal Investigator: Nina Kadan-Lottick
Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Disease/Condition: B-cell Adult Acute Lymphoblastic Leukemia | B-cell Childhood Acute Lymphoblastic Leukemia | T-cell Adult Acute Lymphoblastic Leukemia | T-cell Childhood Acute Lymphoblastic Leukemia | Untreated Adult Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic Leukemia
Principal Investigator: Nina Kadan-Lottick
RTOG 0815: Randomized Trial With or Without Short-Term Androgen Deprivation for Intermediate-Risk Prostate Cancer
Disease/Condition: Prostate | Prostate Cancer
Principal Investigator: Joseph Cardinale
Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD
Disease/Condition: Graft Versus Host Disease | Leukemia, not otherwise specified | Myelodysplastic Syndromes | Non-Hodgkin's Lymphoma
Principal Investigator: Warren Shlomchik
STEAM (Sequencing Triplet with Avastin and Maintenance): Folfoxiri/Bevacizumab Regiments (Concurrent and Sequential) vs. Folfox/Bevacizumab in First-Line Metastatic Colorectal Cancer
Disease/Condition: Colon
Principal Investigator: Howard Hochster
Study of Kidney Tumors in Young Patients
Disease/Condition: Clear Cell Sarcoma of the Kidney | Congenital Mesoblastic Nephroma | Diffuse Hyperplastic Perilobar Nephroblastomatosis | Rhabdoid Tumor of the Kidney | Stage I Renal Cell Cancer | Stage I Wilms Tumor | Stage II Renal Cell Cancer | Stage II Wilms Tumor | Stage III Renal Cell Cancer | Stage III Wilms Tumor | Stage IV Renal Cell Cancer | Stage IV Wilms Tumor | Stage V Wilms Tumor
Principal Investigator: Gary Kupfer
Study of Late-Occurring Complications in Childhood Cancer Survivors
Disease/Condition: Cancer Survivor | Cardiovascular Complications | Hematopoietic/Lymphoid Cancer | Unspecified Childhood Solid Tumor, Protocol Specific
Principal Investigator: Kupfer, Gary
TAU-2014-1: Phase I Trial of Mibefradil Dihydrochloride with Hypofractionated Re-Irradiation Therapy in Treating Patients with Recurrent Glioblastoma Multiforme (GBM)
Disease/Condition: Brain and Nervous System
Principal Investigator: Ranjit Bindra
The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomized, Open-label Phase III Study of MEK162 vs. Physician's Choice of Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum
Principal Investigator: Thomas Rutherford
Yale Pathology Tissue Services (YPTS) Tissue Banking Protocol
Principal Investigator: David Rimm